References
- ChenYWangHHagpoKCortesJTrends in Chronic myeloid leukemia incidence and survival in the United States from 1975–2009Leuk Lymphoma20135471411141723121646
- Gleevec [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2012
- Sprycel [package insert]Princenton, NJBristol-Myers Squibb2012
- Tasigna [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2012
- JabbourEKantarjianHChronic myeloid leukemia: 2012 update on diagnosis, monitoring, and managementAm J Hematol201287111037104523090888
- National Cancer Institute [homepage on the Internet]Chronic Myelogenous Leukemia Treatment Available from: http://www.cancer.govAccessed July 23, 2013
- Bosulif [package insert]New York, NYPfizer Labs2012
- Iclusig [package insert]Cambridge, MAAriad Pharmaceuticals2012
- National Cancer Institute [homepage on the Internet]Childhood Acute Lymphoblastic Leukemia Treatment Available from: http://www.cancer.govAccessed July 23, 2013
- National Cancer Institute [homepage on the Internet]Adult Acute Lymphoblastic Leukemia Treatment Available from: http://www.cancer.govAccessed July 23, 2013
- HoelzerDThielELöfflerHPrognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adultsBlood19887111231313422030
- GaynorJChapmanDLittleCA cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969J Clin Oncol198866101410303163722
- KooHHPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhoodKorean J Pediatr201154310611021738539
- ZuccottoFArdiniECasaleEAngioliniMThrough the “gatekeeper door”: exploiting the active kinase conformationJ Med Chem20105372681269420000735
- ZhouTCommodoreLHuangWSStructural Mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistanceChem Biol Drug Des201177111121118377
- O’HareTShakespeareWCZhuXTAP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceCancer Cell2009165 (401–412)19573806
- CortesJEKantarjianHShahNPPonatinib in refractory Philadelphia chromosome-positive leukemiasN Engl J Med2012367222075208823190221
- US Food and Drug Administration, Center for Drug Evaluation and Research Medical Review Iclusig® NDA 203469 Application Available12212012Silver Spring, MD Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000MedR.pdfAccessed January 16, 2013
- ARIAD PharmaceuticalsARIAD announces initiation of randomized Phase 3 trial of Ponatinib in newly diagnosed patients with chronic myeloid leukemia [press release]Cambridge, MAARIAD Pharmaceuticals [July 27, 2012]. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1719432&highlight=Accessed 12 19, 2012
- National Cancer InstituteCommon Terminology Criteria for Adverse Events v3.0Bethesda, MDNational Cancer Institute2006 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed April 9, 2013
- US Food and Drug Administration, Center for Drug Evaluation and Research, Office Director Decisional Memo 203469 Iclusig® (ponatinib)Silver Spring, MD Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000ODMemo.pdfAccessed April 9, 2013
- Ariad PharmacetuicalsAriad Pipeline Available from: http://www.ariad.com/pipelineAccessed April 24, 2013
- RenMQinHRenRCowellJKPonatinib suppresses the development of myeloid and lymphoid malignanies associated with FGFR1 abnormalitiesLeukemia2013271324022781593